AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10858715 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% PRO 2000 gel
Number of subjects: 73
Study 10858715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PRO 2000 gel
Number of subjects: 73
Study 10858715 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 73
Study 9352145 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) at dosages up to 300 U/kg thrice weekly for 12 weeks
Number of subjects: 25
Study 9352145 — intervention group
Group type: COMPARATOR
Intervention: normal controls (28 individuals)
Number of subjects: 25
Study 8476874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HIV education and counseling)
Number of subjects: 90
Study 8476874 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 90
Study 4065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg single dose)
Number of subjects: 11
Study 4065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg single dose)
Number of subjects: 11
Study 4065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg/day for 10 days)
Number of subjects: 11
Study 4065188 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg/day for 10 days) with alcohol (EtOH)
Number of subjects: 11
Study 4065188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29468454 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus UFT (tegafur/uracil)
Number of subjects: 57
Study 29468454 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 57
Study 26630391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment for 8 weeks
Number of subjects: 28
Study 26630391 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 25254301 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic rAd5 HIV‐1 gag vaccine
Number of subjects: 93
Study 25254301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ATI CA-RNA and CA-DNA
Number of subjects: 93
Study 21500102 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in physical activity
Number of subjects: 365
Study 21500102 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in objective activity
Number of subjects: 365
Study 19721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 19721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 17875950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 50
Study 17875950 — intervention group
Group type: COMPARATOR
Intervention: Intravenous esmolol
Number of subjects: 50
Study 15121485 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 10 mg
Number of subjects: 16
Study 15121485 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 30 mg
Number of subjects: 16
Study 15121485 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 100 mg
Number of subjects: 16
Study 15121485 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 300 mg
Number of subjects: 16
Study 15121485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11673771 — intervention group
Group type: EXPERIMENTAL
Intervention: Test yoghurt (200 g portion containing 5 g of a novel fat emulsion + 1 g milk fat)
Number of subjects: 60
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic drainage (18 elderly and 59 younger patients)
Number of subjects: 191
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage (8 elderly and 48 younger patients)
Number of subjects: 191
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage (11 elderly and 47 younger patients)
Number of subjects: 191
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage without sphincterotomy
Number of subjects: 191
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with severe cholangitis
Number of subjects: 191
Study 9336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with nonsevere cholangitis
Number of subjects: 191
Study 9336514 — intervention group
Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 191
Study 7533904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogs
Number of subjects: 0
Study 7533904 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinase inhibitors
Number of subjects: 0
Study 7533904 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0
Study 2438874 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid (AA) applied topically twice daily for 3 months
Number of subjects: 15
Study 2438874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 387420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinase
Number of subjects: 70
Study 387420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinase and coumarins
Number of subjects: 70
Study 387420 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinase (all patients considered)
Number of subjects: 70
Study 387420 — intervention group
Group type: COMPARATOR
Intervention: Brinase (excluding 10 patients with Buerger's disease)
Number of subjects: 70
Study 31642946 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL intact group
Number of subjects: 16
Study 31642946 — intervention group
Group type: COMPARATOR
Intervention: ACL cut group
Number of subjects: 16
Study 31084969 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 0
Study 31084969 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27786359 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy plus usual care (n=123; 76 in final analyses)
Number of subjects: 251
Study 27786359 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n=128; 105 in final analyses)
Number of subjects: 251
Study 25810023 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine administered per rectum
Number of subjects: 15
Study 25810023 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg MNTX given subcutaneously before 30 mg rectal morphine
Number of subjects: 15
Study 25810023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23690938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions
Number of subjects: 368
Study 23690938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 368
Study 21875860 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 177
Study 21875860 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 177
Study 19176745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity oat bran beverage
Number of subjects: 20
Study 19176745 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity oat bran beverage
Number of subjects: 20
Study 17138914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cost fruit and vegetable items
Number of subjects: 1355
Study 17138914 — intervention group
Group type: COMPARATOR
Intervention: Low-cost fruit and vegetable items
Number of subjects: 1355
Study 17138914 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 1355
Study 17138914 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 1355
Study 17138914 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1355
Study 15529516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3700
Study 15529516 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3700
Study 15529516 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 3700
Study 11403367 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg q.d.
Number of subjects: 115
Study 11403367 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg q.d.
Number of subjects: 115
Study 9755349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (acute pain induced by 0 degrees‐2 degrees C water immersion)
Number of subjects: 160
Study 9755349 — intervention group
Group type: COMPARATOR
Intervention: No pain
Number of subjects: 160
Study 7872033 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic-naive schizophrenic subjects
Number of subjects: 0
Study 7872033 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated subjects with tardive dyskinesia
Number of subjects: 0
Study 7872033 — intervention group
Group type: COMPARATOR
Intervention: Medicated subjects without tardive dyskinesia
Number of subjects: 0
Study 3124618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin (400 micrograms 3 times a day)
Number of subjects: 13
Study 3124618 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous buserelin injection (200 micrograms once daily)
Number of subjects: 13
Study 3124618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin
Number of subjects: 13
Study 3124618 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous buserelin
Number of subjects: 13
Study 3124618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal and subcutaneous buserelin
Number of subjects: 13
Study 31828590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injection (IACSI)
Number of subjects: 40
Study 31828590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injection (IACSI) + Genicular nerve block (GNB)
Number of subjects: 40
Study 30934041 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter titanium-zirconium (Ti-Zr) alloy implants
Number of subjects: 50
Study 30934041 — intervention group
Group type: COMPARATOR
Intervention: Standard-diameter implants
Number of subjects: 50
Study 30934041 — intervention group
Group type: COMPARATOR
Intervention: Both groups (narrow-diameter and standard-diameter implants)
Number of subjects: 50
Study 28166765 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 240
Study 28166765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic training
Number of subjects: 240
Study 28166765 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study 26814462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching toothpaste containing Blue Covarine (BC)
Number of subjects: 75
Study 26814462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching toothpaste without Blue Covarine (WBC)
Number of subjects: 75
Study 26814462 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 75
Study 26814462 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching using 35% hydrogen peroxide (HP35)
Number of subjects: 75
Study 26814462 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching with 10% carbamide peroxide (CP10)
Number of subjects: 75
Study 23835436 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350+E
Number of subjects: 139
Study 23835436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 21574983 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Number of subjects: 347
Study 21574983 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly at weeks 0-11)
Number of subjects: 347
Study 21574983 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections matching active treatment
Number of subjects: 347
Study 17352847 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive T3
Number of subjects: 50
Study 17352847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17241714 — intervention group
Group type: EXPERIMENTAL
Intervention: JE‐PIV vaccine administered in either two or three intramuscular (IM) doses (6.0 or 12.0 mcg each)
Number of subjects: 0
Study 15792018 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation (S-group)
Number of subjects: 0
Study 15792018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NS-group)
Number of subjects: 0
Study 11692097 — intervention group
Group type: EXPERIMENTAL
Intervention: Active avoidance group (home visits with allergen avoidance measures)
Number of subjects: 104
Study 11692097 — intervention group
Group type: COMPARATOR
Intervention: Placebo avoidance group (home visits with placebo measures)
Number of subjects: 104
Study 11692097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no house visits until the end of the first year)
Number of subjects: 104
Study 11692097 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with mite allergy (considered separately)
Number of subjects: 104
Study 11692097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockroach allergen avoidance measures
Number of subjects: 104
Study 9546944 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 30
Study 9546944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7957466 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral groin node dissection (BGND)
Number of subjects: 64
Study 7957466 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 64
Study 7957466 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 64
Study 2441735 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic amniocentesis
Number of subjects: 283
Study 2441735 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound scan
Number of subjects: 283
Study 29843244 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE)
Number of subjects: 21
Study 29843244 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized music sessions
Number of subjects: 21
Study 29843244 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MSSE and individualized music)
Number of subjects: 21
Study 28397158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (12-month community DPP lifestyle intervention)
Number of subjects: 223
Study 25686143 — intervention group
Group type: EXPERIMENTAL
Intervention: RIN-150 (rifampicin 150 mg and isoniazid 75 mg)
Number of subjects: 28
Study 23727264 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg OCA
Number of subjects: 64
Study 23727264 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg OCA
Number of subjects: 64
Study 23727264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined OCA groups
Number of subjects: 64
Study 23727264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21078196 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 21078196 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 21078196 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no therapy)
Number of subjects: 0
Study 18822906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Er'xian Decoction (BED)
Number of subjects: 60
Study 18822906 — intervention group
Group type: COMPARATOR
Intervention: Artificial menstrual cycle therapy (Control)
Number of subjects: 60
Study 16536187 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 1 second (Group 1)
Number of subjects: 20
Study 16536187 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 2 seconds (Group 2)
Number of subjects: 20
Study 16536187 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 3 seconds (Group 3)
Number of subjects: 20
Study 16536187 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 6 seconds (Group 4)
Number of subjects: 20
Study 16536187 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC unit light cured for 12 seconds (Group 5)
Number of subjects: 20
Study 16536187 — intervention group
Group type: COMPARATOR
Intervention: QTH unit light cured for 60 seconds (Group 6)
Number of subjects: 20
Study 14519634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil (5-FU) therapy
Number of subjects: 309
Study 10768906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole (0.5 mg/kg bodyweight)
Number of subjects: 1094
Study 10768906 — intervention group
Group type: COMPARATOR
Intervention: Conventional pretreatment (heparin 15,000 IU and aspirin 500 mg intravenously)
Number of subjects: 1094
Study 8635316 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer case managers
Number of subjects: 0
Study 8635316 — intervention group
Group type: COMPARATOR
Intervention: Non-consumer case managers
Number of subjects: 0
Study 1358922 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin (2‐4 mg/day for 4 weeks)
Number of subjects: 12
Study 4044461 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrodantin (100 mg at night)
Number of subjects: 72
Study 4044461 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (100 mg at night)
Number of subjects: 72
Study 30636727 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week home-based treatment program including orthotics and strengthening exercises
Number of subjects: 35
Study 29498348 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml blood orange juice providing 50 mg anthocyanins/d
Number of subjects: 41
Study 29498348 — intervention group
Group type: COMPARATOR
Intervention: 500 ml blonde orange juice without anthocyanins
Number of subjects: 41
Study 27561137 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health dose (16 kcal/kg/wk) of exercise for 12 weeks
Number of subjects: 122
Study 27561137 — intervention group
Group type: COMPARATOR
Intervention: Low dose (4 kcal/kg/wk) of exercise for 12 weeks
Number of subjects: 122
Study 24041737 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet for 12 h on the day before (Group A)
Number of subjects: 198
Study 24041737 — intervention group
Group type: COMPARATOR
Intervention: High volume polyethylene glycol (50 mL/kg, up to 2Lt/die) (Group B)
Number of subjects: 198
Study 24041737 — intervention group
Group type: COMPARATOR
Intervention: Low volume polyethylene glycol (25 mL/kg, up to 1Lt/die) (Group C)
Number of subjects: 198
Study 24041737 — intervention group
Group type: COMPARATOR
Intervention: 20 mL (376 mg) of oral simethicone (Group D)
Number of subjects: 198
Study 24041737 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL/kg (up to 1Lt/die) of polyethylene glycol solution plus 20 mL (376 mg) of oral simethicone (Group E)
Number of subjects: 198
Study 22513502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 to 20 mg, increased based on effects and adverse reactions)
Number of subjects: 104
Study 22513502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 104
Study 20551183 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic drugs (sorafenib [n = 10], sunitinib [n = 22])
Number of subjects: 51
Study 20551183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 51
Study 20551183 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (n = 7)
Number of subjects: 51
Study 18948239 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment (Group A)
Number of subjects: 296
Study 18948239 — intervention group
Group type: EXPERIMENTAL
Intervention: No amiodarone treatment (Group B)
Number of subjects: 296
Study 18948239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative AF)
Number of subjects: 296
Study 18948239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 296
Study 16198876 — intervention group
Group type: EXPERIMENTAL
Intervention: AR index (echocardiographic parameters: jet width ratio, vena contracta width, pressure half‐time, jet density, diastolic flow reversal in the descending aorta)
Number of subjects: 79
Study 11895046 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng 200 mg/d
Number of subjects: 30
Study 10047624 — intervention group
Group type: EXPERIMENTAL
Intervention: High PRP group (PRP > 21,700)
Number of subjects: 6251
Study 10047624 — intervention group
Group type: COMPARATOR
Intervention: Low PRP group (PRP <= 21,700)
Number of subjects: 6251
Study 8570879 — intervention group
Group type: EXPERIMENTAL
Intervention: Escort spirometer
Number of subjects: 200
Study 8570879 — intervention group
Group type: COMPARATOR
Intervention: mini-Wright peak flow meter
Number of subjects: 200
Study 8570879 — intervention group
Group type: COMPARATOR
Intervention: Micromed turbine spirometer
Number of subjects: 200
Study 1675036 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 113
Study 1675036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 6183864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methoxsalen
Number of subjects: 26
Study 6183864 — intervention group
Group type: COMPARATOR
Intervention: Topical trioxsalen
Number of subjects: 26
Study 6183864 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA-exposed skin
Number of subjects: 26
Study 6183864 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 26
Study 31570024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S combined with mifepristone and misoprostol
Number of subjects: 74
Study 31570024 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone and misoprostol only
Number of subjects: 74
Study 31725473 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus Propentofylline (300 mg/d)
Number of subjects: 48
Study 31725473 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus Placebo
Number of subjects: 48
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional fitness (FF)
Number of subjects: 2096
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: 30s-arm curl
Number of subjects: 2096
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: Language
Number of subjects: 2096
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-foot up-and-go
Number of subjects: 2096